Genmab — Februar 2021
-
Guardant Health - We are pleased to announce that we have submitted supplemental PMAs for our collaboration with Janssen with amivantamab and with Amgen for sotorasib. The selection of Guardant360 CDx as the frontline liquid biopsy device of choice in these two programs demonstrates the growing confidence of biopharma in our IVD offering.
-
Den er da oppe med 1,5%......
-
markedsføringsloven siger noget
-
Returret er ikke bestemt ved lov, men almindelig aftalefrihed:)
-
Det er besynderligt, at se 5-årskursen på Genmab. Det tager lidt at spotte crashet omkring Corona i marts 2020. Det fyldte ellers en del, dengang, men nu kan det knap ses. Hvordan vil vi mon perspektivere om 12 måneder?
-
Meget sigende, at den lå i plus i tossetimen
-
Jan´s udtalelser til Børsen om tredobling har åbenbart ikke haft nogen virkning.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind